

RESEARCH ARTICLE

Open Access

Alternative treatment of serious and mild *Pasteurella multocida* infection in New Zealand White rabbits

Orsolya Palócz^{1*†}, János Gál², Paul Clayton³, Zoltán Dinya⁴, Zoltán Somogyi¹, Csaba Juhász⁵ and György Csikó^{1†}

Abstract

Background: *Pasteurella multocida* causes numerous economically relevant diseases in livestock including rabbits. Immunisation is only variably effective. Prophylactic antibiotics are used in some species but are contra-indicated in rabbits, due to their adverse effects on the rabbit microbiota. There is therefore a substantial need for alternative forms of infection control in rabbits; we investigated the effect of oral β -glucan on *P. multocida* infection in this species.

Results: Thirty-five New Zealand White rabbits were randomly divided into five groups of seven animals. Three groups were inoculated with *Pasteurella multocida* intranasally (in.), a physiologically appropriate challenge which reproduces naturally acquired infection, and received either (1–3), (1–6) β -glucans or placebo. Four other groups were inoculated both in. and intramuscularly (im.), representing a supra-physiological challenge, and received either (1–3), (1–6) β -glucans, antibiotic or placebo. β -glucans given prophylactically were highly effective in protecting against physiological (in.) bacterial challenge. They were less effective in protecting against supra-physiological bacterial challenge (in. and im.), although they extended survival times. This latter finding has practical relevance to breeders as it extends the window in which heavily infected and symptomatic animals can be salvaged with antibiotics.

Conclusions: In our study, (1–3), (1–6) β -glucans were highly effective in protecting against a model of naturally acquired *P. multocida* infection and extended survival times in the supra-physiological model. Enrofloxacin was effective in protecting against supra-physiological infection. We are currently reviewing the use of combined prophylaxis.

Keywords: *Pasteurella multocida*, β -glucan, Rabbit

Background

In infection control, rabbits are important target animals. They are domestic pets, livestock animals in increasing demand for meat and fur production, and a widely used experimental species for human drug research.

Since the European Union (EU) and Regulation (EC) 1831/2003 banned the use of antibiotics as feed additives in 2006, concerted efforts have been made to find alternative prophylactics. To date none of the investigated supplements has shown adequate effectiveness, leading to

reduced feed conversion rates and increased per-head veterinary and other costs [1].

In rabbit production, antibiotics are still commonly used under veterinary prescription during the growth period (weaning – 56/60 days) to prevent post-weaning enteric disorders. However, regulatory changes affecting rabbit production similar to those applied to poultry are expected shortly [2]. As much rabbit production is small to medium scale, many producers will be unable to afford to make substantial changes in husbandry practice. Alternative prophylactics are therefore urgently needed.

Pasteurella multocida, a virulent and readily transmitted coccobacillus, is one of the most significant bacterial diseases of rabbits and causes considerable economic losses in large production units world-wide [3,4]. Clinical signs

* Correspondence: palocz.orsolya@aotk.szie.hu

†Equal contributors

¹Department of Pharmacology and Toxicology, Faculty of Veterinary Science, Szent István University, István u. 2, Budapest 1078, Hungary
Full list of author information is available at the end of the article

in rabbits include rhinitis with purulent nasal discharge, pneumonia, otitis media, pyometra, orchitis, abscesses, oculoconjunctivitis, and septicaemia [5,6]; although infection may also be asymptomatic [7]. Of the 5 serogroups, serogroup A and to a lesser extent serogroup D strains are considered to be causative agents of pasteurellosis in rabbits [8]. Rabbits can become infected with *P. multocida* immediately after birth, and the prevalence of colonization increases with age until about 5 months. Most adult rabbits are believed to be infected with *P. multocida*.

Endemic infection, therefore, remains a source of considerable potential loss. Control measures such as enhanced husbandry and the culling of symptomatic animals reduce overall morbidity and mortality, but impose significant costs. Vaccines targeting *P. multocida* reduce infection but do not give complete protection under field conditions [9]. Antibiotics are due to be phased out, due to such concerns as antibiotic traces in animal products impacting on human health [10]. In any case, and despite initial reports of multiple antibiotic sensitivity, [11,12], the spread of resistance [13] and the hypersensitivity of rabbits to many antibacterial agents precludes the aggressive use of antibiotics in this species [14].

Alternative to antibiotics include probiotics, prebiotics and a number of phytonutrients, none of which is very effective. To this list we must now add the β -glucans, cell wall constituents of bacteria, fungi and plants. The (1–3), (1–6) fungal β -glucans in particular are recognized by mammalian cells as pathogen-associated molecular patterns and thus act as biological response modifiers. This recognition plays an important role in host defense and presents specific opportunities for clinical modulation of the host innate immune response. Experimental and clinical results show that the (1–3), (1–6) β -glucans act as broad-spectrum enhancers of host defense mechanisms, positively influencing the immunological response of mammals including humans to bacterial, viral, and fungal infections [15].

The aim of this present study was to observe and describe the effect of a (1–3), (1–6) β -glucan dietary supplement on physiological and a supra-physiological *P. multocida* infection in rabbits.

Methods

Bacterial isolates and growth conditions

Pasteurella isolates were stored in a solution of 30% glycerol at -80°C . Isolates were grown in tryptic soy broth at 36°C .

For the isolation of *P. multocida* from clinical samples, swabs were streaked onto blood agar plates and incubated at 36°C for 24 hours.

Rabbits, housing and treatments

Thirty-five, clinically healthy, seven week old, 20 female and 15 male New Zealand White rabbits (S & K Lap Nyúltenyésztő Kft., Kartal, Hungary) were used in this study. The animals were housed in stainless steel cages (40×60×80 cm), two rabbits per cage in the animal housing facility of the Department of Pharmacology and Toxicology, acclimated at $20 \pm 2^{\circ}\text{C}$ on a 12 h light 12 h dark schedule. One hundred grams of commercial pellet feed was provided daily, water was available *ad libitum*. A microchip was implanted sub-dermally (cervical region) in each animal for validated identification. The rabbits (mean weight 1105 ± 87 g) were randomly divided into 5 groups (7 rabbits/group) comprising 1 control group and 4 experimental groups: positive controls, antibiotic-treated, low dose β -glucan (5 mg/kg bw.) and high dose β -glucan (50 mg/kg bw.) (Table 1).

The experimental schedule included acclimatization for 7 days, pre-treatment for 14 days, inoculation, and subsequent post-treatment for 7 days. During the pre-treatment phase from day 8 to 21, β -glucan was delivered in aqueous solution via probe, made up with 0.5% w/v methylcellulose. Animals in the control and antibiotic groups received pure methylcellulose solution. After challenge with *P. multocida* (see below), in the control groups the daily single administration of placebo was continued. On the day of challenge and thereafter, animals in the antibiotic group daily received enrofloxacin 10 mg/kg bw., diluted ten times in 0.5% methylcellulose.

Bakers yeast β -glucan (Immivet® 3–6 Dispersible Powder) was supplied by Biothera Company (Eagan, MN 55121, USA).

Methylcellulosum USP; Molar Chemicals Ltd, Budapest, Hungary.

Table 1 Experimental schedule

Group name	Days 8–14 at 8 am	Days 15–21 at 8 am
Control	0.5% methylcellulose 1 ml/kg	0.5% methylcellulose 1 ml/kg
Positive control	0.5% methylcellulose 1 ml/kg	0.5% methylcellulose 1 ml/kg
Antibiotic	0.5% methylcellulose 1 ml/kg	1% enrofloxacin in 0.5% methylcellulose
Small dose beta-glucan	5 mg/kg beta-glucan in 0.5% methylcellulose	5 mg/kg beta-glucan in 0.5% methylcellulose
High dose beta-glucan	50 mg/kg beta-glucan in 0.5% methylcellulose	50 mg/kg beta-glucan in 0.5% methylcellulose

The substances were administered to the rabbits in the concentrations above, according to the time schedule.

Enrofloxacin: Neoflox® 10% internal solution; Tolnagro Ltd., Szekszárd, Hungary.

Bacterial challenge and subsequent monitoring

Bacterial challenges were administered on Day 15. In the three physiological model groups, animals were given in. 0.5 ml physiological saline containing approximately 10⁸ CFU of a cocktail of ten lapine isolates of *P. multocida*. In the four supra-physiological model groups, animals received 0.5 ml of the same bacterial suspension both in. and im. Rectal temperature and clinical status of all rabbits were monitored twice daily. The clinical signs were scored as follows: breathing sound 0 – normal, 1 – respiratory murmur; nasal discharge 0 – absent, 1 – present; conjunctivitis 0 – absent, 1 – present; attitude 0 – active, 1 – depressed; appetite 0 – normal, 1 – decreased. A total clinical score was calculated for each individual rabbit (0–5). Challenged rabbits in the terminal stage of the disease and those which survived until 7 days pi. were euthanized by sodium pentobarbital overdose (100 mg/kg bw. ip., Euthasol® 40% injection, Produlab Pharma B.V., Netherlands).

Pathology

All challenged and control rabbits were examined for gross and histological lesions. Lungs, liver, spleen, kidneys and nasal mucosa were histologically examined in all rabbits. The samples were fixed in 8% neutral buffered formalin for 24 h and embedded in paraffin wax. Sections (3–4 µm) were cut, stained with hematoxylin and eosin, and examined by light microscopy.

PCR analyses and gel electrophoresis

Total DNA of bacterial strains was isolated with E.Z.N. A. bacterial DNS kit (OMEGA Bio-Tek, Norcross, USA) according to the manufacturer's recommendations.

The identity of isolates was confirmed by PCR. PCR was performed using 5PRIME HotMasterMix (5PRIME GmbH, Hamburg, Germany) on the MiniOpticon System (BioRad). For each PCR reaction, 2.5 µl DNA was added directly to a PCR reaction mixture, set to a final volume of 25 µl, containing × 1 concentrated HotMasterMix and 0.2 µM of the appropriate primers. The DNA-sequences of oligonucleotide primers are listed in Table 2. The thermal profile for all reactions was 2 min at 95°C, then 30 cycles of 30 s at 95°C, 30 s at 60°C and 30 s at 72°C. The PCR was terminated with a final extension at 72°C for 5 min.

The PCR amplicons were separated by electrophoresis in 2% agarose gel, the resulting bands were visualised and scanned by the InGenius LHR Gel Documentation and Analysis System (Syngene).

Statistical analyses


Statistical analyses were performed by Statistica 12 software (Statsoft, Tulsa, USA). Differences between means were evaluated by one-way analysis of variance (ANOVA) followed by a post hoc comparison using Fisher's least significant difference (LSD) test. Survival curves were calculated using the Kaplan-Meier method, the curves were compared using the Cox's F test. Statistical significance was set at p < 0.05.

Ethical approval

The experiment was conducted according to approved laboratory animal experimentation ethics regarding to

Table 2 Primer sequences for identification and detection of the virulence associated genes in *P. multocida* strains

Gene	Primer sequence	Accession number	Reference
<i>kmt1</i>	F - ATCCGCTATTTACCCAGTGG	[GenBank:NC_017027]	[21]
	R - GCTGTAAACGAACTCGCCAC		
<i>hyaC-hyaD</i>	F - TGCCAAAATCGCAGTCAG	[GenBank:NZ_CM002276]	[22]
	R - TTGCCATCATTGTCAGTG		
<i>pfhA</i>	F - AGCTGATCAAGTGGTGAAC	[GenBank:NC_016808]	This study
	R - TGGTACATTGGTGAATGCTG		
<i>nanH</i>	F - GAATATTTGGGCGGCAACA	[GenBank:NC_017764]	[23]
	R - TTCTCGCCCTGTCATCACT		
<i>hgbA</i>	F - TGGCGGATAGTCATCAAG	[GenBank:NZ_CM002276]	[23]
	R - CCAAAGAACCACTACCCA		
<i>ompH</i>	F - CGCGTATGAAGTTTGTAGT	[GenBank:NZ_CM001580]	[23]
	R - TTTAGATTGTGCGTAGTCAAC		
<i>ptfA</i>	F - TCCACTCGTTGTGGCATTCA	[GenBank:NC_017027]	This study
	R - AGAAACACCTTGAGCTGCGT		




the national and European law, compatible with the conditions set up by the code of practice for the care and use of animals for experimental purpose. The study was authorised by the Local Institutional Animal Care Committee (Munkahelyi Állatjóléti Bizottság, MÁB) (no. 51/2013).

Results

In the physiological model, at 24 hours after physiological challenge (in. only), infected animals developed conjunctivitis and significantly increased rectal temperature ($p \leq 0.05$), clinical score ranged between 1 and 2. Animals exposed to supra-physiological challenge (in. and im.) had, in addition

to the above, nasal discharge and respiratory murmur, clinical score ranged between 3 and 5. Rectal temperature significantly increased 24 hours after both challenges ($p \leq 0.05$) and ($p \leq 0.01$) (Figures 1 and 2). The control rabbits showed no clinical signs.

In the animals exposed to physiological (in.) challenge, autopsy findings were relatively minor (see Additional file 1); nasal mucosa showed epithelial damage and inflammatory infiltration and the lungs were affected by interstitial pneumonia (Figure 3A-B), but macroscopic lesions did not develop. Tissues collected from the control and β -glucan treated groups were healthy and intact (Figure 3C-D). *P. multocida* was cultured back from all






Figure 3 Representative photomicrographs of (a, c) lung tissue and (b, d) nasal mucosa from rabbits infected intranasally with *P. multocida*. (a) Lung from the positive control (untreated) animals showing interstitial inflammatory reaction, and (c) normal lung from the β -glucan treated animals. (b) Nasal mucosa from the positive control (untreated) animals showing epithelial necrosis and intensive heterophil granulocyte infiltration with submucosal edema. (d) Normal nasal mucosa from the β -glucan treated animals. Hematoxylin and eosin stain; magnification, 100 \times .


challenged rabbits nasal cavities. In the supra-physiological model (rabbits infected in. and im.), autopsy revealed congested heart accompanied with enlarged and congested blood vessels, necrotic foci in the liver, brown peritoneum, congested friable kidneys, and dark brown spleen. Trachea, lungs, and heart were congested, hyperemic and filled with blood. The lungs showed peribronchitis, severely congested vessels with vasculitis, marked alveolar collapse, diffused interstitial inflammatory reaction and intra-alveolar tissue destruction. Positive control and β -glucan animals showed similar pathology. The enrofloxacin treated group had milder symptoms; interstitial pneumonia and *Pasteurella* septicaemia occurred but necrotic lesions and macroscopical signs were not seen. *P. multocida* were cultured back from all inflammatory foci.

β -glucan treatment did not reduce the numbers of deaths in the supra-physiological model but did postpone death by several days. Either low-dose or high-dose β -glucan treatment marginally delayed death but the delay was statistically significant when both β -glucan treatments were compared to the positive control group together (Figure 4). In field conditions, this extended window of opportunity for antibiotic intervention would have considerable implications for veterinary management.

All ten *P. multocida* isolates administered to the rabbits were shown to be sensitive to enrofloxacin in the disk diffusion test. The inhibition zone diameters were between 21–25 mm. All ten *P. multocida* isolates harboured the species-specific gene sequence (*kmt*), porin protein encoding gene (*ompH*), hemoglobin binding protein encoding gene (*hgbA*), filamentous hemagglutinin encoding gene (*pfhA*), neuraminidase gene (*nanH*) and 8 of 10 isolates were contained the type 4 fimbriae gene (*ptfA*). 8 of ten isolates were positive for *capA* capsule biosynthesis gene.

Discussion

In rabbit husbandry, good environmental control is critical in reducing the burden of infection. Common symptoms including nasal discharge, sneezing and conjunctivitis are most frequently due to *Pasteurella multocida*, which is also the major cause of morbidity and mortality. *P. multocida* may also cause abscesses in subcutaneous and other



sites, torticollis, circling due to infection of the inner ear and septicaemia [13].

Fluoroquinolones such as enrofloxacin are concentration-dependent bactericides with activity against many pathogens including *P. multocida*. Tissue levels two to three times higher than that found in the serum have been demonstrated in various species, and the fluoroquinolones are relatively safe in rabbits [16], but questions regarding effectiveness remain. For example, enrofloxacin (5 mg/kg bw.) given orally to rabbit does stopped transmission of *Pasteurella* to their young but failed to eliminate infection from the mother rabbits themselves [17]. Enrofloxacin given at 5 mg/kg im. eliminated *P. multocida* from nearly all adult rabbits but in rabbits given enrofloxacin orally, although the nasal flush cultures were negative, the necropsy cultures from nasopharynx, cavity, tympanic cavity, and lung were all positive [17]. These findings correspond with our results, where animals treated with 10 mg/kg enrofloxacin p.o. showed less serious clinical signs and necropsy alterations, but interstitial pneumonia still occurred.

It is generally acknowledged that Pasteurellosis in rabbits should be managed rather than treated, but the failure of oral enrofloxacin to eradicate *P. multocida* and the subsequent risk of resistance has led to regulatory pressure to phase these drugs out and seek alternatives. The (1–3), (1–6) β -glucans are prime candidates. Numerous studies have shown that these natural compounds exhibit

anti-infective and anti-tumour properties, mediated by immuno-priming. In immuno-priming, β -glucans bind to the CR-3 receptor present on innate immune cells resulting in enhanced chemotaxis, phagocytosis and microbial killing [18]. This has been shown to confer protection against many pathogens including anthrax, a lethal disease that affects animals and humans. In one study conducted in association with the Canadian Department of Defence [19], orally administered Immivet® 3–6 (2 and 20 mg/kg body weight) given for eight days prior to inoculation with *Bacillus anthracis* provided almost complete protection against infection over the 10-day post-exposure test period.

The result of our study indicates that clinical disease caused by physiological exposure to *P. multocida* can be prevented with oral β -glucans. This protective action should enable reduced antibiotic use in livestock and pets, leading to improved food safety and reduced spread of resistance. The immuno-priming activity of the (1–3), (1–6) β -glucans when given together with antibiotics has been shown to increase the effectiveness of the antibiotics [20]. This will be evaluated in further trials.

Conclusions

Supra-physiological exposure to *P. multocida* (in. and im. inoculation) is lethal in rabbits. Physiological exposure (in. only) creates a milder and non-lethal infection. We used *Pasteurella* isolates with serious virulence-associated genes (*ompH*, *hgbA*, *pfhA*, *nanH*, *ptfA*). After supra-physiological exposure, only the enrofloxacin treatment was clinically effective, and even the antibiotic treated group suffered from septicaemia. β -glucan treatment did not prevent death, although it delayed death considerably compared to controls. β -glucan was, however, highly effective in protecting against physiological exposure to *P. multocida*, preventing any histological damage. Our results suggest that β -glucan feeding should be preventive against clinical Pasteurellosis in rabbits.

Additional file

Additional file 1: Evaluation of the histological sections of lungs, spleen, liver, kidneys, and nasal mucosa derived from the intranasally challenged (*P. multocida*) rabbits. The +/- indicates the presence/absence of histopathological alterations, respectively.

Abbreviations

bw.: bodyweight; CFU: colony forming unit; CR-3: complement receptor 3; im.: intramuscular; in.: intranasal; ip.: intraperitoneal; MÁB: Munkahelyi Állatjóléti Bizottság (Local Institutional Animal Care Committee); pi.: postinfection; *P.*: *Pasteurella*; p.o.: per os; SEM: standard error of mean.

Competing interests

The authors declare that they have no competing interests.

Authors' contributions

GyCs conceived the experiment, designed the trial, coordinated the individual steps of the study, examined the rabbits and helped draft the manuscript. OP did the bacterial culturing, carried out the PCR analyses, participated in the study coordination and drafted the manuscript. JG carried out the pathology examination and histology tests. ZS participated in the treatment and examination of the animals and helped to perform the gel electrophoresis. CsJ and ZD participated in the design of the study and helped to draft the manuscript. PC reconfigured and supervised the manuscript. All authors read and approved the final manuscript.

Acknowledgements

The study was supported by the Research Faculty Grant 2013 of the Szent István University, Faculty of Veterinary Science (grant no. KK-UK-12003). We would like to thank Éva Borbás for her tireless work for caring the rabbits and to Márta Hegyvári for her assistance. We are grateful to Dr. Zoltán Németh for providing us with the *Pasteurella* isolates.

Author details

¹Department of Pharmacology and Toxicology, Faculty of Veterinary Science, Szent István University, István u. 2, Budapest 1078, Hungary. ²Department of Exotic Animal and Wildlife Medicine, Faculty of Veterinary Science, Szent István University, István u. 2, Budapest 1078, Hungary. ³Institute for Food, Brain and Behaviour, 106-108, Cowley Road, Oxford, OX41JE, UK. ⁴Flavon Group Hungary, Veres Péter u. 19, Debrecen 4033, Hungary. ⁵Immitec Nutrition AB, Farmannsveien 18-22, Tønsberg 3111, Norway.

Received: 27 May 2014 Accepted: 10 November 2014

Published online: 25 November 2014

References

1. Thacker PA: Alternatives to antibiotics as growth promoters for use in swine production: a review. *J Anim Sci Biotechnol* 2013, **4**(1):35.
2. Bovera F, Lestingi A, Marono S, Iannaccone F, Nizza S, Mallardo K, de Martino L, Tateo A: Effect of dietary mannan-oligosaccharides on in vivo performance, nutrient digestibility and caecal content characteristics of growing rabbits. *J Anim Physiol Anim Nutr (Berl)* 2012, **96**(1):130–136.
3. Jaglic Z, Jeklova E, Leva L, Kummer V, Kucerova Z, Faldyna M, Maskova J, Nedbalcova K, Alexa P: Experimental study of pathogenicity of *Pasteurella multocida* serogroup F in rabbits. *Vet Microbiol* 2008, **126**(1–3):168–177.
4. Soriano-Vargas E, Vega-Sanchez V, Zamora-Espinosa JL, Acosta-Dibarrat J, Aguilar-Romero F, Negrete-Abascal E: Identification of *Pasteurella multocida* capsular types isolated from rabbits and other domestic animals in Mexico with respiratory diseases. *Trop Anim Health Prod* 2012, **44**(5):935–937.
5. El Tayeb AB, Morishita TY, Angrick EJ: Evaluation of *Pasteurella multocida* isolated from rabbits by capsular typing, somatic serotyping, and restriction endonuclease analysis. *J Vet Diagnostic Invest: Official Publication Of The Am Association Of Vet Lab Diagn, Inc* 2004, **16**(2):121–125.
6. Nassar SA, Mohamed AH, Soufy H, Nasr SM: Protective effect of Egyptian propolis against rabbit pasteurellosis. *Biomed Res Int* 2013, **2013**:163724.
7. Sanchez S, Mizan S, Quist C, Schroder P, Juneau M, Dawe D, Ritchie B, Lee MD: Serological response to *Pasteurella multocida* NanH sialidase in persistently colonized rabbits. *Clin Diagn Lab Immunol* 2004, **11**(5):825–834.
8. Dabo SM, Confer AW, Montelongo M, Lu YS: Characterization of rabbit *Pasteurella multocida* isolates by use of whole-cell, outer-membrane, and polymerase chain reaction typing. *Lab Anim Sci* 1999, **49**(5):551–559.
9. Suckow MA, Haab RW, Milosic LJ, Guilloud NB: Field trial of a *Pasteurella multocida* extract vaccine in rabbits. *J Am Assoc Lab Anim Sci* 2008, **47**(1):18–21.
10. Ahmad TA, Rammah SS, Sheweita SA, Haroun M, El-Sayed LH: Development of immunization trials against *Pasteurella multocida*. *Vaccine* 2014, **32**(8):909–917.
11. Lizarazo YAV, Ferri EFR, de la Fuente AJM, Martin CBG: Evaluation of changes in antimicrobial susceptibility patterns of *Pasteurella multocida* subsp *multocida* isolates from pigs in Spain in 1987–1988 and 2003–2004. *Am J Vet Res* 2006, **67**(4):663–668.
12. Sellyei B, Varga Z, Szentesi-Samu K, Kaszanyitzky E, Magyar T: Antimicrobial susceptibility of *Pasteurella multocida* isolated from swine and poultry. *Acta Vet Hung* 2009, **57**(3):357–367.

13. Martino PA, Luzi F: Bacterial infections in rabbit as companion animal: a survey of diagnostic samples in Italy. In *Proceedings of the 9th World Rabbit Congress, Verona, Italy, 10–13 June 2008*. Edited by Xicato G, Trocino A, Lukefahr SD. Castanet-Tolosan; France: World Rabbit Science Association; 2008:1013–1018.
14. Fann MK, O'Rourke D: Normal bacterial flora of the rabbit gastrointestinal tract: A clinical approach. *Semin Avian and Exotic Pet Med* 2001, **10**(1):45–47.
15. Hofer M, Pospisil M: Modulation of animal and human hematopoiesis by beta-glucans: a review. *Molecules* 2011, **16**(9):7969–7979.
16. Redrobe S: Rabbit therapeutics: safe, effective, or deadly? In *Small animal and exotics Proceedings of the North American Veterinary Conference, Orlando, Florida, USA, 16–20 January 2010*. Gainesville; USA: The North American Veterinary Conference; 2010:1778–1780.
17. Suckow MA, Martin BJ, Bowersock TL, Douglas FA: Derivation of *Pasteurella multocida*-free rabbit litters by enrofloxacin treatment. *Vet Microbiol* 1996, **51**(1–2):161–168.
18. Vetvicka V, Vetvickova J: Physiological effects of different types of beta-glucan. *Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub* 2007, **151**(2):225–231.
19. Kournikakis B, Mandeville R, Brousseau P, Ostroff G: Anthrax-protective effects of yeast beta 1,3 glucans. *MedGenMed* 2003, **5**(1):1.
20. Tzianabos AO, Cisneros RL: Prophylaxis with the immunomodulator PGG glucan enhances antibiotic efficacy in rats infected with antibiotic-resistant bacteria. *Ann N Y Acad Sci* 1996, **797**:285–287.
21. Townsend KM, Frost AJ, Lee CW, Papadimitriou JM, Dawkins HJ: Development of PCR assays for species- and type-specific identification of *Pasteurella multocida* isolates. *J Clin Microbiol* 1998, **36**(4):1096–1100.
22. Townsend KM, Boyce JD, Chung JY, Frost AJ, Adler B: Genetic organization of *Pasteurella multocida* cap Loci and development of a multiplex capsular PCR typing system. *J Clin Microbiol* 2001, **39**(3):924–929.
23. Ewers C, Lubke-Becker A, Bethe A, Kiebling S, Filter M, Wieler LH: Virulence genotype of *Pasteurella multocida* strains isolated from different hosts with various disease status. *Vet Microbiol* 2006, **114**(3–4):304–317.

doi:10.1186/s12917-014-0276-6

Cite this article as: Palócz et al.: Alternative treatment of serious and mild *Pasteurella multocida* infection in New Zealand White rabbits. *BMC Veterinary Research* 2014 **10**:276.

Submit your next manuscript to BioMed Central and take full advantage of:

- Convenient online submission
- Thorough peer review
- No space constraints or color figure charges
- Immediate publication on acceptance
- Inclusion in PubMed, CAS, Scopus and Google Scholar
- Research which is freely available for redistribution

Submit your manuscript at
www.biomedcentral.com/submit

